日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized)

Eyluxvi(阿柏西普)与 Eylea 在新生血管性年龄相关性黄斑变性中的治疗等效性:ALTERA 试验(随机)

Raczynska, Dorota; Ernest, Jan; Baumane, Kristine; Sagong, Min; Akiyama, Kunihiko; Rauschning, Winrich; Vajas, Attila; Nowosielska, Agnieszka; Dusova, Jaroslava; Majtánová, Nora; Oleksy, Piotr; Kuneva, Irina; Resch, Miklos; Lange, Natalia; Briede, Eliza; Bajdik, Beáta; Jeong, Areum; Kozub, Barbara; Papp, Andras

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study

在保加利亚常规临床实践中,胰岛素格列净 300 U/mL 用于治疗使用 NPH 或预混胰岛素控制不佳的 2 型糖尿病患者的真实世界有效性和安全性:ToUPGRADE 研究

Kamenov, Zdravko; Pehlivanova, Veselina; Kuneva, Tsvetodara; Kirilov, Kiril; Bobeva, Roza; Stoykova, Julija; Mihalevska, Svetla

Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study

在保加利亚常规临床实践中,利西拉肽作为口服降糖药的附加疗法,其真实世界疗效和安全性评估:LIXODAR 研究

Temelkova, Nataliya; Vladeva, Stefka; Delchev, Aleksi; Ivanova, Kalina; Gerasimova-Zheleva, Yoanna; Kuneva, Tsvetodara; Pehlivanova, Veselina; Popivanov, Plamen